Muscle Preservation in the GLP-1 Era: Metabolic Quality, Anabolic Therapeutics, and the Future of Active Longevity

Incretin-based pharmacotherapy has fundamentally restructured obesity medicine, elevating body composition quality and skeletal muscle preservation over total mass loss as the definitive benchmark for longevity. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide (marketed as Ozempic and Wegovy) and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists such as tirzepatide demonstrate unprecedented clinical efficacy, driving total body weight reductions between 15% and 22% in major clinical trials. However, widespread adoption of these agents has sparked substantial clinical concern regarding the quality of weight lost, specifically the concurrent depletion of lean body mass (LBM) and functional skeletal muscle.
Skeletal muscle functions not merely as a mechanical actuator for locomotion, but as a primary metabolic organ responsible for postprandial glucose disposal, basal metabolic rate regulation, myokine secretion, and functional independence across the human lifespan. The rapid catabolism of muscle tissue alongside adipose tissue threatens to induce sarcopenic obesity in vulnerable populations, compromise physical capacity, and precipitate rebound weight regain characterized by adverse body composition shifts. Consequently, the longevity sector, digital fitness platforms, biopharmaceutical developers, and clinical operators are pivoting toward multi-modal frameworks designed to preserve functional muscle mass during profound pharmacologically induced energy deficits.

Scientific Consensus on Incretin-Induced Lean Mass Loss versus Caloric Restriction Physiology

Caloric restriction inherently triggers systemic nitrogen catabolism, rendering lean body mass loss an obligate physiological response to energy deficits across all weight loss modalities rather than an isolated drug-induced toxicity. Understanding the distinction between direct drug-induced sarcopenia and systemic catabolic responses to severe caloric restriction is essential for establishing rational clinical management protocols.

The Physiology of Lean Mass Loss Across Weight Loss Modalities

Energy deprivation forces the human organism to mobilize stored endogenous substrates to satisfy baseline metabolic demand. While adipose tissue triglyceride hydrolysis supplies the majority of required energy, systemic proteolysis inevitably breaks down structural proteins to yield glucogenic amino acids. Historical nutritional literature establishes the “quarter fat-free mass rule,” which observes that conventional dietary energy restriction typically results in approximately 25% of total weight loss coming from fat-free mass (FFM), with the remaining 75% coming from fat mass.
When weight loss acceleration is extreme—such as during water fasting or post-bariatric surgical procedures—the proportion of FFM loss rises dramatically. Fasting interventions can acutely yield FFM losses of 50% to 60%, whereas bariatric surgery cohorts consistently demonstrate FFM loss proportions ranging between 19% and 24%. Pharmacological therapies, including sodium-glucose cotransporter-2 inhibitors (SGLT2i) and older GLP-1 RAs such as liraglutide, display FFM loss percentages ranging from 20% to 50% depending on baseline adiposity, energy deficit depth, and concurrent physical activity.

Trial Analysis: Semaglutide (STEP 1) versus Tirzepatide (SURMOUNT-1)

Clinical evaluation of body composition in incretin registration trials highlights distinct tissue loss trajectories between selective GLP-1 RAs and dual GLP-1/GIP RAs. In the STEP 1 trial body composition substudy utilizing dual-energy X-ray absorptiometry (DEXA), adults receiving weekly semaglutide 2.4 mg (Wegovy) lost an average of 15% total body weight over 68 weeks. Total fat mass decreased by 19.3%, while total lean body mass decreased by 9.7%. Expressed as a proportion of total weight lost, fat-free mass accounted for approximately 39% to 45.5% of total mass reduction (-6.92 kg lean mass loss versus -15.2 kg total weight loss in raw DEXA cohorts).
Conversely, the SURMOUNT-1 trial substudy evaluating tirzepatide (a dual GIP/GLP-1 receptor agonist) demonstrated a superior tissue selectivity profile. Participants treated with high-dose tirzepatide achieved a 21.3% mean body weight reduction over 72 weeks, comprising a 33.9% reduction in fat mass and a 10.9% reduction in lean mass. The proportion of weight lost as lean mass was calculated at approximately 25% (-5.26 kg lean mass loss versus -15.3 kg total weight loss).
Crucially, the placebo arm in SURMOUNT-1 exhibited an identical 25% lean mass loss proportion during diet and lifestyle-induced weight reduction. This finding indicates that tirzepatide-mediated lean mass loss reflects standard physiological weight loss dynamics rather than a drug-specific catabolic insult. The discrepancy between semaglutide and tirzepatide lean loss ratios may stem from GIP receptor engagement in white adipose tissue, which enhances lipid buffer capacity, optimizes nutrient partitioning, and accelerates adipocyte lipolysis relative to skeletal muscle proteolysis.

Differentiating Lean Body Mass from Functional Skeletal Muscle Mass

A critical flaw in popular discourse surrounding incretin-induced weight loss is the conflation of DEXA-measured Lean Body Mass (LBM) with skeletal muscle tissue. DEXA technology quantifies body composition via dual-energy photon attenuation, segmenting mass into bone mineral content, fat mass, and fat-free soft tissue (LBM). LBM encompasses total body water, intracellular and extracellular hydration, liver, kidney, and gastrointestinal tissue mass, structural collagen, and skeletal muscle tissue.
Lean Body Mass is composed of four primary physiological compartments:

• Total Body Water (50%–60% of LBM): Rapidly fluctuates based on glycogen stores and fluid shifts. Caloric restriction depletes liver and muscle glycogen, shedding bound water without altering structural muscle protein.
• Visceral Organ Mass: High-fat diet-induced hepatomegaly and gastrointestinal hypertrophy rapidly regress during caloric restriction, reducing measured LBM without degrading limb skeletal muscle.
• Structural Connective Tissue: Matrix collagen and vascular beds remain relatively stable during acute body mass changes.
• Skeletal Muscle Mass: The true target for metabolic protection and functional preservation, comprising contractile sarcomere units.

When individuals initiate GLP-1 therapy, rapid anorectic caloric restriction leads to liver glycogen depletion, with each gram of stored glycogen losing approximately 3 grams of bound water. Furthermore, visceral organs undergo metabolic downsizing; high-fat diet-induced hepatomegaly and intestinal hypertrophy rapidly regress during caloric restriction, dropping measured LBM without degrading limb skeletal muscle. Mouse models and translational human studies demonstrate that liver tissue mass drops proportionally more than gastrocnemius or quadriceps muscle mass during semaglutide therapy.
Moreover, clinical trial data reveal that physical functionality and relative strength often improve despite absolute LBM declines. In the prospective SEMALEAN study evaluating semaglutide 2.4 mg over 12 months, participants experienced a 13% total weight reduction and a 19% fat mass reduction. Lean mass dropped by 5% during early treatment before reaching a stable plateau. Despite absolute LBM loss, participant handgrip strength improved significantly, and the clinical prevalence of sarcopenic obesity dropped from 49% at baseline to 33% at 12 months. Similarly, real-world computed tomography (CT) cohorts confirm that while absolute cross-sectional muscle area decreases slightly, functional mobility and relative strength per unit of body mass increase due to the elimination of excess body fat burdens.

Multi-Modal Interventions for Muscle Preservation: Exercise, Protein Kinetics, and AI Autoregulation

Progressive resistance exercise combined with targeted amino acid ingestion provides the mandatory anabolic mechanical and biochemical signaling required to stimulate muscle protein synthesis during incretin-mediated hypocaloric states. Unassisted voluntary diet reduction under GLP-1 therapy frequently leads to inadequate protein intake and sedentary behavior, exacerbating muscle proteolysis.

Resistance Exercise Prescription for Incretin-Treated Individuals

Mechanical tension applied across skeletal muscle fibers represents the most potent physiological signal to stimulate muscle protein synthesis (MPS) and downregulate muscle RING-finger protein-1 (MuRF1)-mediated ubiquitin-proteasome degradation pathways. Resistance exercise provides an essential anabolic stimulus that counteracts the systemic catabolic signals generated by profound energy deficits.
The clinical protocol evaluated in ongoing trials, such as the LEAN-PREP randomized controlled trial, establishes a structured, pragmatic home- or facility-based resistance training regimen:

• Weekly Frequency: A minimum of 3 non-consecutive days per week, allowing adequate recovery windows between training sessions.
• Exercise Selection: Focus on multi-joint compound movements engaging major muscle groups (e.g., squats, deadlifts/hip hinges, chest presses, rows, and overhead presses) to maximize systemic motor unit recruitment and myokine response.
• Intensity and Volume: Progression from 1 set toward 3 sets per exercise, utilizing an intensity corresponding to 60–80% of 1-repetition maximum (1RM), or a Rating of Perceived Exertion (RPE) of 7 to 9 on a 10-point scale.
• Progressive Overload: Systematic increases in resistance, repetition volume, or density every 2 to 4 weeks to ensure continuous mechanical strain as body weight decreases.

Meta-analyses of resistance training during energy restriction confirm that structured strength exercise fully attenuates muscle strength loss, preserves fat-free mass (standardized mean difference SMD: 0.40), and significantly enhances total fat mass loss (SMD: -0.36) compared to diet restriction alone.

Nutritional Interventions and Protein Kinetics

Incretin-induced suppression of central appetite signaling regularly causes total daily protein intake to fall below physiological maintenance thresholds. When daily protein consumption drops below 0.8 g/kg/day during rapid weight loss, skeletal muscle tissue is hyper-sensitized to catabolism.
To preserve nitrogen balance and maximize fractional synthetic rates of muscle tissue, total protein intake must be elevated substantially above baseline recommended dietary allowances:

• Target Intake Range: Clinical guidelines dictate a daily protein intake between 1.2 g/kg and 1.6 g/kg of total body weight per day (or 1.6 g/kg to 2.3 g/kg of fat-free mass).
• Leucine Threshold Optimization: To effectively trigger the mechanistic target of rapamycin complex 1 (mTORC1) pathway and initiate MPS, individual meal feedings must provide a minimum threshold of 2.5 g to 3.0 g of the essential amino acid leucine. This corresponds to approximately 25 g to 30 g of high-quality intact protein per feeding window.
• Daily Distribution: Protein consumption should be distributed across 3 to 4 discrete feeding intervals throughout the day, rather than skewed into a single evening meal, ensuring sustained plasma amino acid availability.
• Formulation Adaptation for Anorexic States: Given GLP-1-induced delayed gastric emptying and early satiety, solid food protein sources can induce gastrointestinal discomfort. High-density liquid protein isolate supplements (whey, casein, or optimized essential amino acid blends) serve as essential adherence tools to hit daily targets without overloading gastric volume.

The AI Fitness Stack: Precision Autoregulation and Adaptive Nutrition

Artificial intelligence systems provide the necessary adaptive control layer to bridge the gap between drug-induced appetite suppression and rigorous anabolic compliance. Because incretin therapy alters appetite and metabolic rates dynamically over time, static diet and training plans quickly become ineffective.
An advanced AI Fitness Stack operating alongside GLP-1 therapy integrates three core algorithmic modules:

• Computer-Vision Micro and Macro Nutrient Tracking: Computer-vision algorithms analyze meal images to estimate protein density, leucine content, and overall caloric load in real time. When the system detects that GLP-1-induced anorexia is causing a user to miss daily protein thresholds, it automatically suggests high-density, low-volume supplemental options.
• Biometric Deficit Autoregulation: Machine learning models process continuous physiological inputs—including weight decay velocity from smart scales, resting heart rate, heart rate variability (HRV), and sleep efficiency. If weight loss velocity exceeds safe thresholds (e.g., >1.5% of body weight per week), indicating elevated lean mass catabolism risk, the algorithm dynamically recalibration caloric targets upward to stabilize lean tissue.
• Adaptive Resistance Training Load Balancing: AI coaching platforms utilize autoregulatory algorithms (such as Velocity-Based Training adjustments or dynamic RPE scaling) to alter daily training volume based on systemic fatigue and caloric deficit depth. When energy availability is low, the AI reduces overall set volume while maintaining mechanical intensity, preventing overtraining-induced muscle breakdown while preserving neuromuscular signaling.

Next-Generation Anabolic Therapeutics and the Commercial Longevity Ecosystem

Combining centrally acting anorectic incretins with peripherally acting anabolic agents represents the pharmaceutical frontier for selective adiposity reduction and skeletal muscle preservation. These emerging pharmacological modalities aim to completely decouple fat loss from muscle loss.

Activin Type II Receptor Blockade: The Bimagrumab + Semaglutide Paradigm

Bimagrumab is a fully human monoclonal antibody that selectively binds to activin type II receptors (ActRIIA and ActRIIB), competitively inhibiting the binding of myostatin (Growth Differentiation Factor 8) and Activin A. Myostatin and Activin A act as potent negative regulators of skeletal muscle growth, driving SMAD2/3 transcription factor phosphorylation to suppress protein synthesis and induce muscle atrophy. Furthermore, activin receptor signaling in adipose tissue inhibits lipid mobilization; blocking this pathway increases lipolysis and brown/beige fat thermogenic gene expression.
Complementary mechanisms govern the combination of bimagrumab and semaglutide:

• Semaglutide (Central Anorectic Mechanism): Activates GLP-1 receptors in the brainstem and hypothalamus, slowing gastric emptying and reducing appetite to lower overall caloric intake.
• Bimagrumab (Peripheral Anabolic & Lipolytic Mechanism): Blocks ActRIIA/ActRIIB receptors in muscle and fat tissue, inhibiting myostatin/activin A to stimulate mTORC1-mediated muscle hypertrophy while accelerating adipocyte lipolysis.
• Combined Synergy: Produces profound body weight and fat mass reduction while protecting muscle mass from energy deficit-induced catabolism.

Results from the randomized, double-blind, placebo-controlled Phase 2b BELIEVE trial (NCT05616013) presented at the 85th Scientific Sessions of the American Diabetes Association (ADA) demonstrate the efficacy of combined Activin receptor blockade and GLP-1 RA therapy:

• Trial Architecture: The study evaluated 507 adults with obesity across 9 treatment arms over 72 weeks, comparing bimagrumab monotherapy (10 or 30 mg/kg IV every 12 weeks), semaglutide monotherapy (1.0 or 2.4 mg SC weekly), and combination regimens.
• Body Weight Reduction: High-dose combination therapy (bimagrumab 30 mg/kg + semaglutide 2.4 mg) achieved a mean 22.1% total body weight reduction (-24.2 kg) at week 72, outperforming semaglutide 2.4 mg alone (-15.7% / -16.5 kg) and bimagrumab 30 mg/kg alone (-10.8% / -12.0 kg).
• Tissue-Selective Loss Partitioning: In the high-dose combination arm, 92.8% of total weight lost was derived directly from fat mass, compared to 71.8% for semaglutide monotherapy and 100% for bimagrumab monotherapy.
• Lean Mass Preservation: Semaglutide monotherapy resulted in a 7.4% reduction in lean body mass. Bimagrumab monotherapy increased lean mass by +2.5%. The high-dose combination successfully limited lean mass loss to just 2.9% (versus semaglutide alone), effectively neutralizing the muscle-wasting effect of semaglutide.
• Visceral Adiposity and Inflammatory Markers: Combination therapy achieved a 45.7% reduction in total body fat mass and a 58.2% reduction in estimated visceral adipose tissue (VAT), compared to 27.8% fat mass and 35.8% VAT reductions with semaglutide alone. High-sensitivity C-reactive protein (hsCRP) decreased by 83.4%, and cardioprotective adiponectin levels surged by 37.9%.
• Functional Capacity: Participants on combination therapy demonstrated statistically significant improvements in SF-36 Physical Functioning scores compared to semaglutide alone.

Safety profiles in the BELIEVE trial showed tolerable adverse events consistent with both drug classes. Bimagrumab was associated with transient muscle spasms, mild diarrhea, and acne, alongside temporary early elevations in ALT and lipase levels, while semaglutide-related events remained predominantly gastrointestinal. Discontinuation rates due to adverse events stood at 9% in combination groups over 72 weeks.

Gerozyme Targeted Therapies: 15-PGDH Inhibition for Stem Cell-Mediated Muscle Regeneration

Research led by Helen Blau’s laboratory at Stanford University identified 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as a master “gerozyme”—an enzyme whose expression increases natively with aging and tissue injury, actively driving tissue degradation.
15-PGDH functions as the primary rate-limiting catabolic enzyme that degrades Prostaglandin E (PGE2), a crucial lipid signaling molecule required for muscle stem cell (MuSC) proliferation, mitochondrial bioenergetic rejuvenation, and myofiber repair. In aged skeletal muscle or during severe metabolic stress, elevated 15-PGDH depletes intracellular PGE pools, rendering MuSCs quiescent and impairing regenerative capacity.
In preclinical research published in PNAS, Stanford researchers demonstrated that while semaglutide treatment in obese mice drives substantial fat mass reduction, it significantly reduces skeletal muscle mass and impairs muscle stem cell-mediated regeneration following injury or strain. When mice received semaglutide monotherapy, myofiber cross-sectional area decreased, and force recovery following muscle strain was severely blunted.
Co-administration of an oral small-molecule 15-PGDH inhibitor (PGDHi) completely surmounts these impairments:

• Stem Cell Activation: PGDHi restored endogenous PGE levels, stimulating MuSC proliferation and myogenic differentiation within semaglutide-treated muscle tissue.
• Structural and Functional Recovery: Co-treated animals exhibited full restoration of regenerated myofiber cross-sectional area and complete functional recovery of contractile force, overcoming the muscle damage repair deficits caused by GLP-1 monotherapy.
• Metabolic Non-Interference: 15-PGDH inhibition enhanced muscle repair and strength without altering semaglutide’s central appetite suppression or reducing total fat mass loss.

An experimental oral 15-PGDH inhibitor, MF-300 (developed by Epirium Bio in partnership with Stanford University), has completed Phase 1 human clinical trials, establishing safety and tolerability. Phase 2b clinical trials are evaluating MF-300 for age-related sarcopenia, with researchers positioning 15-PGDH inhibitors as potential companion therapeutics to be co-prescribed with GLP-1 RAs to prevent muscle wasting.

Institutional Investment and Operational Outlook: Convergence of Incretin Therapy, Anabolic Tech, and Longevity Clinics

The business model of metabolic health is transitioning from stand-alone weight loss clinics to integrated longevity ecosystems that combine incretin prescription, muscle preservation biopharma, AI fitness coaching, and advanced biomarker tracking. Venture capital and private equity allocations are shifting toward businesses capable of managing metabolic quality rather than crude scale weight reduction.
An integrated metabolic longevity ecosystem merges three core pillars:

1. Pharmacological Core: Combining GLP-1/GIP receptor agonists with next-generation anti-catabolic agents (ActRII inhibitors like Bimagrumab, 15-PGDH gerozyme inhibitors like MF-300) to ensure tissue-selective mass loss.
2. Anabolic & Digital Protocols: Deploying AI-guided resistance training programs, leucine-dense targeted nutritional supplementation, and biowearable integration to maintain mechanical strain and nitrogen balance.
3. Diagnostic & Biomarker Hub: Utilizing serial DEXA/3D body scanning alongside continuous protein breakdown sensors to track real-time tissue trajectories and prevent sarcopenic degradation.

This infrastructure drives commercial value creation by maintaining patient basal metabolic rate, preventing post-treatment weight rebound, and delivering durable long-term active aging outcomes. Longevity clinics adopting this integrated model position themselves to capture the expanding active aging demographic.

Strategic Takeaways and Industry Roadmap

The long-term viability of incretin medicine depends on shifting clinical success metrics from total scale mass reduction to body composition optimization and active longevity1—a core theme of the Market Intelligence Report category on fitnessnav.

Actionable Roadmap for Key Stakeholders

• Clinical Practitioners: Establish baseline body composition metrics via DEXA or advanced multi-frequency BIA before initiating GLP-1 RA therapy. Mandate concurrent resistance training (3 sessions weekly) and prescribe daily protein intakes between 1.2 g/kg and 1.6 g/kg, utilizing liquid protein isolate supplements to circumvent GLP-1-induced early satiety.
• Digital Health & Fitness Platforms (fitnessnav.com): Integrate computer-vision nutritional tracking and continuous biowearable data feeds to monitor user weight loss velocity. Implement automated alerts when weight loss exceeds 1.5% of body weight per week, dynamically recalibrating daily set volumes and protein targets to protect lean mass.
• Biopharmaceutical & Healthcare Investors: Direct venture and growth capital toward combination therapeutics that preserve muscle during severe energy deficits. Key growth assets include monoclonal antibodies targeting ActRII receptors (e.g., bimagrumab) and gerozyme-inhibiting small molecules (e.g., 15-PGDH inhibitors), alongside digital platforms delivering autoregulated resistance exercise co-therapy.

By synthesizing incretin-induced caloric reduction with progressive resistance exercise, targeted amino acid nutrition, AI-driven autoregulation, and novel anti-catabolic therapeutics, the health and longevity industry can eliminate the trade-off between fat loss and muscle retention. This comprehensive approach ensures that the metabolic benefits of modern weight loss therapies translate into durable physical performance, preserved functional capacity, and expanded healthspan.

Works cited

1. GLP-1 and Muscle Loss: How to Know What Weight You’re Really Losing - We Are BOD Inc., https://www.wearebod.com/blogs/journal/glp-1-and-muscle-loss-how-to-know-what-weight-you-re-really-losing
2. ADA 2025: Combination of Bimagrumab and Semaglutide Shows Enhanced Fat Loss and Muscle Preservation | Pharmacy Times, https://www.pharmacytimes.com/view/ada-2025-combination-of-bimagrumab-and-semaglutide-shows-enhanced-fat-loss-and-muscle-preservation
3. BELIEVE: Bimagrumab/Semaglutide Combo Yields Substantial Fat Mass Weight Loss, Preserves Lean Mass | HCPLive, https://www.hcplive.com/view/believe-bimagrumab-semaglutide-combo-yields-substantial-fat-mass-weight-loss-preserves-lean-mass
4. https://www.snaq.ai/blog/does-ozempic-cause-muscle-loss-research
5. Does Ozempic Cause Muscle Loss? Here’s What the Research Actually Shows - SNAQ, https://www.snaq.ai/blog/does-ozempic-cause-muscle-loss-research
6. Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss? | Circulation, https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.067676
7. Semaglutide and GLP-1: Effects on lean body mass still unclear, https://www.drugdiscoverytrends.com/glp-1-impact-lean-mass/
8. LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial | BMJ Open, https://bmjopen.bmj.com/content/16/4/e116911
9. LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial | Request PDF - ResearchGate, https://www.researchgate.net/publication/404088011_LEAN_mass_Preservation_with_Resistance_Exercise_and_Protein_during_semaglutide_and_tirzepatide_therapy_LEAN-PREP_study_a_protocol_for_a_randomised_controlled_trial
10. Drug enhances muscle repair during GLP-1 weight-loss treatment in mice, https://med.stanford.edu/news/all-news/2026/06/muscle-glp-1.html
11. LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide Therapy - ClinicalTrials.Veeva, https://ctv.veeva.com/study/lean-mass-preservation-with-resistance-exercise-and-protein-during-semaglutide-tirzepatide-therapy
12. Do GLP-1 drugs cause muscle loss?, https://www.drugs.com/medical-answers/glp-1-drugs-cause-muscle-loss-3582339/
13. Bimagrumab-Semaglutide Combination Achieves Significant Weight Loss While Preserving Muscle Mass | Pharmacy Times, https://www.pharmacytimes.com/view/bimagrumab-semaglutide-combination-achieves-significant-weight-loss-while-preserving-muscle-mass
14. LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial - PubMed, https://pubmed.ncbi.nlm.nih.gov/42020128/
15. Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotyping | medRxiv, https://www.medrxiv.org/content/10.64898/2026.04.11.26350687v.full-text
16. Semaglutide reduces excess body fat in people with obesity | Endocrine Society, https://www.endocrine.org/news-and-advocacy/news-room/featured-science-from-endo-2021/semaglutide-reduces-excess-body-fat-in-people-with-obesity
17. Full article: Tirzepatide for overweight and obesity management - Taylor & Francis, https://www.tandfonline.com/doi/full/10.1080/14656566.2024.2436595
18. Glucagon-like peptide-1 receptor agonists and muscle: interpreting lean mass changes in clinical care | Global Cardiology, https://www.globalcardiology.info/site/article/view/101/235
19. Does Tirzepatide Cause Muscle Loss? Clinical Evidence and Prevention - Fella Health, https://www.fellahealth.com/guide/does-tirzepatide-cause-muscle-loss
20. Inhibidores de Geroenzimas: el mapa 2 | KRECE, https://krece.io/longevidad/inhibidores-geroenzimas/
21. Simple: Weight Loss & Health Coaching, https://simple.life/
22. Combination bimagrumab plus semaglutide confers weight loss while preserving lean mass, https://www.healio.com/news/endocrinology/20250623/combination-bimagrumab-plus-semaglutide-confers-weight-loss-while-preserving-lean-mass
23. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial - PubMed, https://pubmed.ncbi.nlm.nih.gov/41772149/
24. 15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist–induced weight loss - PNAS, https://www.pnas.org/doi/pdf/10.1073/pnas.2606533123
25. Research | Blau Lab - Stanford Medicine, https://med.stanford.edu/blau-lab/research.html
26. 15-PGDH Inhibition Overcomes Muscle Regenerative Deficit Seen With GLP1-Receptor Agonist–Induced Weight Loss | bioRxiv, https://www.biorxiv.org/content/10.64898/2026.02.26.708119v.full-text
27. 15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist–induced weight loss | PNAS, https://www.pnas.org/doi/10.1073/pnas.2606533123
28. The worn cartilage behind your aching knees might finally regrow, now that researchers have learned to block a single aging protein - OkDiario, https://okdiario.com/metabolic/en/nutrition/the-worn-cartilage-behind-your-aching-knees-might-finally-regrow-now-that-researchers-have-learned-to-block-a-single-aging-protein-29279/
29. Berlin Bio Hackathon x Adaptyv: 15-PGDH Binder Design, https://proteinbase.com/competitions/nucleate-berlin-adaptyv-15pgdh
30. Combination GLP-1 Therapy Shows Fat Mass Loss While Preserving Lean Mass in Adults with Obesity - Pennington Biomedical Research Center, https://www.pbrc.edu/news/media/2026/semaglutide_and_bimagrumab.aspx